실적분석 2026년 7월 31일

BrightSpring Health Services ($BTSG) Q2 2026 Earnings Analysis — Revenue and Adjusted EPS Both Beat; Full-Year Guidance Raised

Earnings Scorecard

Revenue: $3.873 billion (+23.0% year-over-year, estimate $3.663 billion) ✅ Beat

EPS (Earnings Per Share): Adjusted EPS $0.45 (estimate $0.40) ✅ Beat

Guidance: Raised — Full-year 2026 revenue raised to $15.10–$15.43 billion, adjusted EBITDA raised to $820–$845 million

Stock Reaction: After-hours +0.16% ($73) — As of 21:01 Korea time on July 31

What Went Well

Revenue and earnings both beat: Revenue of $3.873 billion and adjusted EPS of $0.45 exceeded expectations

Accelerating profitability: Adjusted EBITDA of $206 million, +44.2% year-over-year

Full-year guidance raised: Revenue and adjusted EBITDA outlooks both lifted

This quarter reflects continuing operations only following the divestiture of the Community Living business (completed March 30, 2026). Pharmacy Solutions revenue reached $3.407 billion (+22%) and Provider Services revenue $466 million (+30%), with both pillars growing in tandem; segment-adjusted EBITDA also rose 41% to $255 million. On the pharmacy side, prescription unit pricing and gross profit per script rose 22% and 28%, respectively, driving a larger earnings contribution, while Provider Services saw home-health average daily patient census grow 54% year-over-year, supporting top-line expansion. Net leverage ratio declined to 2.15x from 2.27x in the prior quarter, and the company noted that $300 million in senior debt repayment and refinancing reduced interest expense.

What Fell Short

Flat prescription volume: Script fills virtually unchanged at ~0%, leaving growth reliant on pricing and mix

Comparison-base caution: Continuing-operations basis post-divestiture limits direct comparison with historical totals

Supply-demand and regulatory risk: Secondary offering by sponsor affiliates, Medicare and Medicaid reimbursement rate volatility

Pharmacy Solutions prescription fill volume came in at roughly 10.84 million scripts, essentially flat year-over-year. Revenue and earnings growth depend heavily on rising revenue per script ($314.20) and gross profit per script ($27.50), so a reversal in the higher-priced mix or any change in drug pricing and reimbursement structure could slow the growth pace. Separately, in June KKR affiliates and certain members of management conducted a secondary offering of common stock, and the company repurchased approximately 1,026,465 shares from the underwriters for $60 million. Independent of the results, the sponsor stake-sale issue remains a near-term supply-demand variable. Given the healthcare services sector's characteristics, changes in Medicare and Medicaid rates and payment methodology, as well as third-party payor cost controls and post-payment audits, were explicitly cited risk factors in the press release that could affect achievement of guidance.

What Management Said

Management assessed that Q2 results reflect quality-focused operations, service levels, and a commitment to patients, stating that the company will continue to focus on disciplined execution and effective care delivery. For the full-year outlook, the company raised revenue and adjusted EBITDA guidance on a basis that excludes Community Living and does not include the impact of any future new acquisitions, and views the Amedisys and LHC Group branch acquisitions as contributing approximately $35 million to 2026 adjusted EBITDA. From a market standpoint, the tone reads as solid growth now confirmed in the numbers with the annual bar raised another notch, but with only adjusted EBITDA guidance — and no EPS guidance — provided, there is room on the earnings call to probe further into earnings quality and one-time items.

Market Reaction and What to Watch Next

Despite the strong beat and raised full-year guidance, the after-hours reaction was little changed. Revenue and adjusted EPS both came in ahead of expectations and profitability metrics were steep, but the stock appears to have already priced in much of the strong-growth expectation ahead of the release, while caution over flat prescription volume, post-divestiture comparison-base shifts, and sponsor secondary offering supply weighed on sentiment. Direction should become clearer with post-open trading and the day's earnings call, once persistence of pharmacy pricing, the organic vs. acquisition mix behind home-health patient census growth, and the conservatism of the raised full-year revenue and adjusted EBITDA guidance are clarified.

Monitor whether pharmacy prescription pricing and gross profit per script gains extend into the next quarter.

Watch whether home-health average daily patient census growth holds up without acquisition contribution.

Track progress against the raised full-year revenue and adjusted EBITDA guidance, including the half-year run rate and realization of the second-half acquisition contribution (~$35 million).